The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Kinase Drug Discovery – What’s Next in the Field?
Open accessAbstract
Over the past 15 years protein kinases have become the pharmaceutical industry's most important class of drug target in the field of cancer. Some 20 drugs that target kinases have been approved for clinical use over the past decade, and hundreds more are undergoing clinical trials. However, the recent approval of the first protein kinase inhibitors for the treatment of inflammatory diseases, coupled with an enhanced understanding of the signaling networks that control the immune system, suggests that there will be a surge of interest in this area over the next 10 years. In this connection, we discuss opportunities for targeting protein kinases in the MyD88 signaling network for the development of drugs to treat chronic inflammatory and autoimmune diseases. Activating mutations in protein kinases underlie many other diseases and conditions, and we also discuss why the protein kinases SPAK/OSR1 and LRRK2 have recently become interesting targets for the treatment of hypertension and Parkinson's disease, respectively, and the progress that has been made in developing LRRK2 inhibitors. Finally we suggest that more focus on the identification of inhibitors of kinase activation, rather than kinase activity, may pay dividends in identifying exquisitely specific inhibitors of signal transduction cascades, and we also highlight "pseudo-kinases" as an attractive and unexplored area for drug development that merits much more attention in the years to come.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., & Saltiel, A. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27489 · Cited by 3,393
Self-citationA protein kinase involved in the regulation of inflammatory cytokine biosynthesis
Lee, J. C., Laydon, J. T., McDonnell, P. C., Gallagher, T. F., Kumar, S., Green, D., McNulty, D., Blumenthal, M. J., Keys, J. R., Land vatter, S. W., et al. (1994) · Nature · doi:10.1038/372739a0 · Cited by 3,288
Heidenreich, P. A., Trogdon, J. G., Khavjou, O. A., Butler, J., Dracup, K., Ezekowitz, M. D., Finkelstein, E. A., Hong, Y., Johnston, S. C., Khera, A., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820a55f5 · Cited by 3,208
(1995) · FEBS Letters · doi:10.1016/0014-5793(95)00357-f · Cited by 2,086
Human Hypertension Caused by Mutations in WNK Kinases
Wilson, F. H., Disse-Nicodème, S., Choate, K. A., Ishikawa, K., Nelson-Williams, C., Desitter, I., Gunel, M., Milford, D. V., Lipkin, G. W., Achard, J.-M., et al. (2001) · Science · doi:10.1126/science.1062844 · Cited by 1,487
Hirai, H., Sootome, H., Nakatsuru, Y., Miyama, K., Taguchi, S., Tsujioka, K., Ueno, Y., Hatch, H., Majumder, P. K., Pan, B.-S., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1012 · Cited by 860
Molecular Physiology and Pathophysiology of Electroneutral Cation-Chloride Cotransporters
Gamba, G. (2005) · Physiological Reviews · doi:10.1152/physrev.00011.2004 · Cited by 810
LKB1-Dependent Signaling Pathways
Alessi, D. R., Sakamoto, K., & Bayascas, J. R. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142702 · Cited by 788
Self-citationEmerging roles of pseudokinases
Boudeau, J., Miranda-Saavedra, D., Barton, G. J., & Alessi, D. R. (2006) · Trends in Cell Biology · doi:10.1016/j.tcb.2006.07.003 · Cited by 547
Self-citationVitari, A. C., Deak, M., Morrice, N. A., & Alessi, D. R. (2005) · Biochemical Journal · doi:10.1042/bj20051180 · Cited by 503
Self-citationTong, Y., Yamaguchi, H., Giaime, E., Boyle, S., Kopan, R., Kelleher, R. J., & Shen, J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004676107 · Cited by 501
Uematsu, S., Sato, S., Yamamoto, M., Hirotani, T., Kato, H., Takeshita, F., Matsuda, M., Coban, C., Ishii, K. J., Kawai, T., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042372 · Cited by 488
Jaleel, M., Nichols, R. J., Deak, M., Campbell, D. G., Gillardon, F., Knebel, A., & Alessi, D. R. (2007) · Biochemical Journal · doi:10.1042/bj20070209 · Cited by 472
Self-citationCharacterization of a selective inhibitor of the Parkinson's disease kinase LRRK2
Deng, X., Dzamko, N., Prescott, A., Davies, P., Liu, Q., Yang, Q., Lee, J.-D., Patricelli, M. P., Nomanbhoy, T. K., Alessi, D. R., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.538 · Cited by 417
Self-citationKu, C.-L., von Bernuth, H., Picard, C., Zhang, S.-Y., Chang, H.-H., Yang, K., Chrabieh, M., Issekutz, A. C., Cunningham, C. K., Gallin, J., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070628 · Cited by 399
BARNETT, S. F., DEFEO-JONES, D., FU, S., HANCOCK, P. J., HASKELL, K. M., JONES, R. E., KAHANA, J. A., KRAL, A. M., LEANDER, K., LEE, L. L., et al. (2005) · Biochemical Journal · doi:10.1042/bj20041140 · Cited by 396
Nichols, R. J., Dzamko, N., Morrice, N. A., Campbell, D. G., Deak, M., Ordureau, A., Macartney, T., Tong, Y., Shen, J., Prescott, A. R., et al. (2010) · Biochemical Journal · doi:10.1042/bj20100483 · Cited by 386
Self-citationDzamko, N., Deak, M., Hentati, F., Reith, A. D., Prescott, A. R., Alessi, D. R., & Nichols, R. J. (2010) · Biochemical Journal · doi:10.1042/bj20100784 · Cited by 372
Self-citationStructure of the LKB1-STRAD-MO25 Complex Reveals an Allosteric Mechanism of Kinase Activation
Zeqiraj, E., Filippi, B. M., Deak, M., Alessi, D. R., & van Aalten, D. M. F. (2009) · Science · doi:10.1126/science.1178377 · Cited by 365
Self-citationHerzig, M. C., Kolly, C., Persohn, E., Theil, D., Schweizer, T., Hafner, T., Stemmelen, C., Troxler, T. J., Schmid, P., Danner, S., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr348 · Cited by 360
Richardson, C., Rafiqi, F. H., Karlsson, H. K. R., Moleleki, N., Vandewalle, A., Campbell, D. G., Morrice, N. A., & Alessi, D. R. (2008) · Journal of Cell Science · doi:10.1242/jcs.025312 · Cited by 357
Self-citationCrystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition
Wu, W.-I., Voegtli, W. C., Sturgis, H. L., Dizon, F. P., Vigers, G. P. A., & Brandhuber, B. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012913 · Cited by 331
The kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signaling
Ananieva, O., Darragh, J., Johansen, C., Carr, J. M., McIlrath, J., Park, J. M., Wingate, A., Monk, C. E., Toth, R., Santos, S. G., et al. (2008) · Nature Immunology · doi:10.1038/ni.1644 · Cited by 326
Whole-genome association study identifies STK39 as a hypertension susceptibility gene
Wang, Y., O'Connell, J. R., McArdle, P. F., Wade, J. B., Dorff, S. E., Shah, S. J., Shi, X., Pan, L., Rampersaud, E., Shen, H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808358106 · Cited by 298
The regulation of salt transport and blood pressure by the WNK-SPAK/OSR1 signalling pathway
Richardson, C., & Alessi, D. R. (2008) · Journal of Cell Science · doi:10.1242/jcs.029223 · Cited by 295
Self-citationSPAK-Knockout Mice Manifest Gitelman Syndrome and Impaired Vasoconstriction
Yang, S.-S., Lo, Y.-F., Wu, C.-C., Lin, S.-W., Yeh, C.-J., Chu, P., Sytwu, H.-K., Uchida, S., Sasaki, S., & Lin, S.-H. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009121295 · Cited by 278
Genetic Analysis of Pathways to Parkinson Disease
Hardy, J. (2010) · Neuron · doi:10.1016/j.neuron.2010.10.014 · Cited by 274
Leucine-Rich Repeat Kinase 2 Mutations and Parkinson's Disease: Three Questions
Greggio, E., & Cookson, M. R. (2009) · ASN Neuro · doi:10.1042/an20090007 · Cited by 272
Role of the WNK‐activated SPAK kinase in regulating blood pressure
Rafiqi, F. H., Zuber, A. M., Glover, M., Richardson, C., Fleming, S., Jovanović, S., Jovanović, A., O'Shaughnessy, K. M., & Alessi, D. R. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.200900058 · Cited by 267
Self-citationKontoyiannis, D., Boulougouris, G., Manoloukos, M., Armaka, M., Apostolaki, M., Pizarro, T., Kotlyarov, A., Forster, I., Flavell, R., Gaestel, M., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020281 · Cited by 266
Paradoxical activation of Raf by a novel Raf inhibitor
Hall-Jackson, C. A., Eyers, P. A., Cohen, P., Goedert, M., Tom Boyle, F., Hewitt, N., Plant, H., & Hedge, P. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)80088-x · Cited by 265
Self-citationCalleja, V., Laguerre, M. S., Parker, P. J., & Larijani, B. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000017 · Cited by 256
Clark, K., MacKenzie, K. F., Petkevicius, K., Kristariyanto, Y., Zhang, J., Choi, H. G., Peggie, M., Plater, L., Pedrioli, P. G. A., McIver, E., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215450109 · Cited by 250
Self-citationRonkina, N., Kotlyarov, A., Dittrich‐Breiholz, O., Kracht, M., Hitti, E., Milarski, K. L., Askew, R., Marušić, S., Lin, L.-L., Gaestel, M., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01456-06 · Cited by 216
Targeting protein kinases for the development of anti-inflammatory drugs
Cohen, P. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.01.015 · Cited by 207
Self-citationPyrrolopyridine Inhibitors of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK-2)
Anderson, D. R., Meyers, M. J., Vernier, W. F., Mahoney, M. W., Kurumbail, R. G., Caspers, N., Poda, G. I., Schindler, J. F., Reitz, D. B., & Mourey, R. J. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0611004 · Cited by 170
Estrada, A. A., Liu, X., Baker-Glenn, C., Beresford, A., Burdick, D. J., Chambers, M., Chan, B. K., Chen, H., Ding, X., DiPasquale, A. G., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301020q · Cited by 162
[29] Assay and expression of mitogen-activated protein kinase, MAP kinase kinase, and Raf
Alessi, D. R., Cohen, P., Ashworth, A., Cowley, S., Leevers, S. J., & Marshall, C. J. (1995) · Methods in Enzymology · doi:10.1016/s0076-6879(95)55031-3 · Cited by 158
Self-citationPseudokinases-remnants of evolution or key allosteric regulators?
Zeqiraj, E., & van Aalten, D. M. F. (2010) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2010.10.001 · Cited by 150
Reith, A. D., Bamborough, P., Jandu, K. S., Andreotti, D., Mensah, L. M., Acheson-Dossang, P., Choi, H. G., Deng, X., Zhang, J., Alessi, D. R., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.06.104 · Cited by 149
Self-citationIRAK-4 Inhibitors for Inflammation
Wang, Z., Wesche, H., Stevens, T., Walker, N. P. C., & Yeh, W. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609789044407 · Cited by 149
Zeqiraj, E., Filippi, B., Goldie, S. P., Navratilova, I. H., Boudeau, J., Deák, M., Alessi, D. R., & van Aalten, D. M. F. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000126 · Cited by 149
Self-citationMAPKAP Kinase 2-Deficient Mice Are Resistant to Collagen-Induced Arthritis
Hegen, M., Gaestel, M., Nickerson‐Nutter, C. L., Lin, L., & Telliez, J. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.3.1913 · Cited by 147
MO25 is a master regulator of SPAK/OSR1 and MST3/MST4/YSK1 protein kinases
Filippi, B., Heros, P. D. L., Mehellou, Y., Navratilova, I. H., Gourlay, R., Deák, M., Plater, L., Toth, R. L., Zeqiraj, E., & Alessi, D. R. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.78 · Cited by 143
Self-citationBrain Penetrant LRRK2 Inhibitor
Choi, H. G., Zhang, J., Deng, X., Hatcher, J. M., Patricelli, M. P., Zhao, Z., Alessi, D. R., & Gray, N. S. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300123a · Cited by 140
Self-citationRousseau, S., Papoutsopoulou, M., Symons, A., Cook, D., Lucocq, J. M., Prescott, A. R., O’Garra, A., Ley, S. C., & Cohen, P. (2008) · Journal of Cell Science · doi:10.1242/jcs.018671 · Cited by 134
Self-citationMourey, R. J., Burnette, B., Brustkern, S. J., Daniels, J. S., Hirsch, J. L., Hood, W. F., Meyers, M. J., Mnich, S. J., Pierce, B. S., Saabye, M. J., et al. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.166173 · Cited by 131
Green, C., Göransson, O., Kular, G. S., Leslie, N. R., Gray, A., Alessi, D. R., Sakamoto, K., & Hundal, H. S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802623200 · Cited by 113
Self-citationRönnblom, L., Alm, G. V., & Eloranta, M. (2009) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32832e089e · Cited by 111
Structural insights into the recognition of substrates and activators by the OSR1 kinase
Villa, F., Goebel, J., Rafiqi, F. H., et al. (2007) · EMBO Reports · doi:10.1038/sj.embor.7401048 · Cited by 109
Gilsbach, B. K., Ho, F. Y., Vetter, I. R., Haastert, P. J. M. V., Wittinghofer, A., & Kortholt, A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203223109 · Cited by 101
Clinical relevance of JAK2 (V617F) mutant allele burden
Passamonti, F., & Rumi, E. (2009) · Haematologica · doi:10.3324/haematol.2008.001271 · Cited by 92
High-Frequency Variant p.T60M in NaCl Cotransporter and Blood Pressure Variability in Han Chinese
Shao, L., Lang, Y., Wang, Y., Gao, Y., Zhang, W., Niu, H., Liu, S., & Chen, N. (2012) · American Journal of Nephrology · doi:10.1159/000339165 · Cited by 20
Cited by
Kinase inhibitors: the road ahead
Ferguson, F. M., & Gray, N. S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.21 · Cited by 1,009
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.10.021 · Cited by 886
Properties of FDA-approved small molecule protein kinase inhibitors
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.006 · Cited by 554
Comprehensive characterization of the Published Kinase Inhibitor Set
Elkins, J. M., Fedele, V., Szklarz, M., Abdul Azeez, K. R., Salah, E., Mikolajczyk, J., Romanov, S., Sepetov, N., Huang, X.-P., Roth, B. L., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3374 · Cited by 323
Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor
Thomson, D. W., Poeckel, D., Zinn, N., Rau, C., Strohmer, K., Wagner, A. J., Graves, A. P., Perrin, J., Bantscheff, M., Duempelfeld, B., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00027 · Cited by 103
Metadata
- Authors
- Cohen, P., & Alessi, D. R.
- Venue
- ACS Chemical Biology
- Publisher
- American Chemical Society (ACS)
- Published
- 2012-12-31
- Volume
- 8
- Issue
- 1
- Pages
- 96-104
- ISSN
- 1554-8929 (ISSN-L)
- 1554-8937
- OpenAlex
- W1966285532
- Cited by
- 377
- References
- 53
- FWCI
- 14.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
